Bedwetting in children: what actually works, and what to try first

For a child who wets the bed and wants to stop, the treatment with the best evidence for a lasting cure is the enuresis alarm: in randomised trials about two-thirds of children became dry while using one, and nearly half of those who stuck with it stayed dry after treatment ended [s1]. The medicine desmopressin works faster but the wetting usually returns once it is stopped, which is why guidelines treat it as a different tool for a different need [s1] [s3]. Neither is a first move — the starting point is reassurance, because bedwetting is common and not the child's fault [s3].

What bedwetting is, and when it counts as a problem

Nocturnal enuresis — bedwetting during sleep — is a normal stage of development that most children grow out of, and NICE advises that active treatment is not generally offered to children under five [s3]. It becomes something to address when it persists and distresses the child or family. The condition is not a behavioural failing; guidance is explicit that children should never be punished for wetting, and that punitive approaches are both wrong and counterproductive [s3]. Before any device or drug, the guideline recommends practical steps: sensible daytime fluid intake, regular toileting, and treating constipation if it is present, since a full bowel can drive night-time wetting — the subject of our coverage of chronic constipation.

The alarm: the strongest evidence for a cure

The most reliable summary of alarm treatment is a Cochrane review of 55 trials involving 3,152 children, of whom 2,345 used an alarm [s1]. The device wakes the child at the first drops of urine, training them over weeks to wake to a full bladder or to hold on through the night. Compared with no treatment, about two-thirds of children became dry during alarm use (the risk ratio for failure was 0.38, 95% confidence interval 0.33 to 0.45) [s1].

The more important number is what happens afterwards. Nearly half of the children who persisted with the alarm remained dry after treatment finished, against almost none of those given no treatment (a failure-or-relapse rate of 55% versus 99%; RR 0.56, 95% CI 0.46 to 0.68) [s1]. That durability is the alarm's distinguishing feature. The review also found that relapse was reduced when "overlearning" — deliberately increasing fluids once dryness is achieved — was added (RR 1.92, 95% CI 1.27 to 2.92), or when dry-bed training was combined with the alarm (RR 2.0, 95% CI 1.25 to 3.20) [s1]. Penalties for wet beds, by contrast, appeared counterproductive [s1].

The trade-off is that the alarm demands weeks of committed effort from an often tired household, and it does not work instantly. The review noted that although desmopressin may act more immediately, alarms appeared more effective by the end of a course of treatment (RR 0.71) [s1].

The drugs: faster, but the effect leans on continued use

Desmopressin, a synthetic version of the hormone that reduces urine production overnight, is the main medication. It can produce dry nights quickly, which makes it useful for short-term needs such as a school trip or a sleepover, but the benefit generally depends on continuing to take it [s1] [s3]. A 2025 network meta-analysis of pharmacological treatments pooled 23 randomised trials covering 1,658 children [s2]. It found that combination therapy — most often desmopressin plus an anticholinergic drug — produced higher complete and partial response rates than any single drug; combinations containing desmopressin were superior to desmopressin alone for complete response (risk ratio 3.55, 95% credible interval 2.28 to 5.64) [s2].

Two limits sit alongside that finding. None of the drug regimens significantly improved the relapse rate, meaning they manage the symptom more than they cure the tendency [s2]. And although the review reported that all the treatments produced few adverse events, it cautioned that the small number and size of the trials weakened the strength of the evidence [s2]. Desmopressin also carries a specific safety consideration: because it works by concentrating urine, drinking too much fluid around a dose can lower blood sodium, so guidance pairs it with advice to limit fluids in the evening [s3].

How to read this without overreaching

The evidence supports a sequence rather than a single answer. Reassurance and simple measures come first; for a lasting cure the alarm has the best-supported record; and desmopressin is the tool when a fast, temporary result is what a family needs [s1] [s2] [s3]. What the evidence does not support is treating a young child who will most likely outgrow it, or expecting medication alone to resolve the underlying tendency.

The caveats are real. The alarm trials varied in quality, and success depends heavily on a family's ability to persist [s1]; the drug evidence rests on small trials with limited follow-up [s2]. As with our coverage of potty-training timing, the honest message is that development runs on its own clock, and most children get there.

This article is informational and is not medical advice. It does not recommend any device, medication or dose for an individual child; decisions about assessing or treating bedwetting belong with the child, their family, and a qualified clinician.